Three Phase III Studies of Imbruvica Presented at ASCO Annual Meeting

Tafasitamab + lenalidomide and R-CHOP improves PFS, phase III frontMIND trial finds

The phase III frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi/Minjuvi), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP alone as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma or high-grade B-cell lymphoma, has produced positive results.

June 12, 2026

Vol.52 No.23

Drugs & Targets

FDA grants Fast Track designation for STX-0712 for r/r CMML

FDA has granted Fast Track designation to STX-0712, an investigational therapy in development for the treatment of relapsed or refractory chronic myelomonocytic leukemia.

May 29, 2026

Vol.52 No.21

Clinical Roundup

“Forever chemicals” may be linked to childhood leukemia, UC Irvine study finds

Early exposure to PFAS, a group of widely used compounds known as “forever chemicals,” was associated with a higher risk of acute lymphoblastic leukemia, the most common childhood cancer, according to researchers at the University of California, Irvine Joe C. Wen School of Population & Public Health.

May 01, 2026

Vol.52 No.17

Guest Editorial

Directing the narrative of your survival: How The Remission Film Festival centers survivorship stories

Cancer survivorship in the United States now tops 18 million people. That is a lot of people walking around with a shared experience, and yet somehow we barely talk about what surviving cancer actually does to you.

April 24, 2026

Vol.52 No.16

By Edward Miskie

Drugs & Targets

FDA approves Tecartus for r/r mantle cell lymphoma

FDA granted full approval to Tecartus (brexucabtagene autoleucel), Kite’s CAR T-cell therapy, for adult patients with relapsed or refractory mantle cell lymphoma.

April 03, 2026

Vol.52 No.13

Drugs & Targets

FDA and EC approve Opdivo IO combinations in classical Hodgkin Lymphoma

FDA granted approval of Opdivo (nivolumab) in combination with doxorubicin, vinblastine, and dacarbazine for the treatment of adult and pediatric patients 12 years and older with previously untreated Stage 3 or 4 classical Hodgkin Lymphoma.

March 27, 2026

Vol.52 No.12

Three Phase III Studies of Imbruvica Presented at ASCO Annual Meeting

YOU MAY BE INTERESTED IN

Tafasitamab + lenalidomide and R-CHOP improves PFS, phase III frontMIND trial finds

FDA grants Fast Track designation for STX-0712 for r/r CMML

“Forever chemicals” may be linked to childhood leukemia, UC Irvine study finds

Directing the narrative of your survival: How The Remission Film Festival centers survivorship stories

FDA approves Tecartus for r/r mantle cell lymphoma

FDA and EC approve Opdivo IO combinations in classical Hodgkin Lymphoma

Renew today!

Subscriber content

Never miss an issue!

Login